




FIG. 1




FIG. 2

300




FIG. 3




FIG. 4


500 

FIG. 5




FIG. 6

	Risk Score
0 Med	0
1-5 Meds	1
6-10 Meds	3
11-15 Meds	6
16-21 Meds	9
22+ Meds	12
Anticholinergic Burden score	Actual value of ACB score (i.e. ACB score = 6 then Risk score = 6) MAXIMUM Score = 6
Sedative Burden Score	Actual value of SB score (i.e. SB score = 3 then Risk score = 3) MAXIMUM Score = 5
Competitive inhibition: INHIBITOR and SUBSTRATE	5 MAXIMUM SCORE = 5
Competitive inhibition: INDUCER and SUBSTRATE	5 MAXIMUM SCORE = 5
Competitive inhibition: 3 SUBSTRATES SAME ISOENZYME	3 MAXIMUM SCORE = 6
Competitive inhibition: 2 SUBSTRATES SAME ISOENZYME	2 MAXIMUM SCORE = 4
LQTS SCORE	0-4 = 0 4.5-7.5 = 2 8-11 = 5 11.5-15 = 7 15+ = 10
Pharmacogenomics CYP2D6 substrates	5 MAXIMUM SCORE = 5
Pharmacogenomics CYP2C19 substrates	3 MAXIMUM SCORE = 3
Pharmacogenomics CYP2C9 substrates	3 MAXIMUM SCORE = 3
Pharmacogenomics CYP3A4 substrates	2 MAXIMUM SCORE = 1
RENAL FUNCTION (TBD)	MAXIMUM SCORE 10
TOTAL SCORE	Add all individual Risk Score values (Maximum score is 75)

FIG. 7

Risk Factor	Percentiles at high risk	Number of Patients
Total Risk Score	10.14%	30633
Medication Count	13.91%	42045
Cognitive Impairment	9.11%	27521
Sedation	11.78%	35610
Heart-Rhythm Impairment	2.60%	7847
Competitive Inhibition	11.19%	33813

FIG. 8

Individualized Risk Score Visualization

RISK SCORE 19/50




FIG. 9

PATIENT INFORMATION

eMTM Date: 5/6/2016

First Name:

Last Name:

Gender: Male

Race: White or Caucasian

Estimated CrCl: UNKNOWN

Adherence Score: 1=Medium Adherence

MRPs = medication-related problems

DOB: 09/15/1948 (67 years)

MRPs: Not Specified

Prescriber: TFP

Location: TFP

EXECUTIVE SUMMARY OF RECOMMENDATIONS: [PLEASE REFER TO PAGE 5 FOR FULL RATIONALE]

1. Decrease dose or discontinue Canagliflozin due to renal impairment.

☐ ACCEPT RECOMMENDATION

☐ ACCEPT WITH CHANGES:

☐ NO CHANGE - AWARE OF RECOMMENDATION

2. Consider discontinuing proton pump inhibitor therapy (via step down therapy) or, at minimum, decreasing the dose of pantoprazole.

☐ ACCEPT RECOMMENDATION

☐ ACCEPT WITH CHANGES:

☐ NO CHANGE - AWARE OF RECOMMENDATION

3. Consider replacing Metoprolol with Bisoprolol as an alternative due to a (a) drug-gene interaction, and (b) drug-drug interaction.

☐ ACCEPT RECOMMENDATION

☐ ACCEPT WITH CHANGES:

☐ NO CHANGE - AWARE OF RECOMMENDATION

GENETIC RESULTS SNAPSHOT

ATM CYP4F2

CYP2C19 SLC01B1

CYP2C9 TPMT

CYP2D6 VKORC1

CYP3A4 CYP3A5

ApoE

Thrombosis Profile:

F2 F5 MTHFR (A>C) MTHFR (C>T)

No variant

1 variant

≥1 [decreased] variants

≥1 [increased] variants

PRE-INTERVENTION

Total Meds: 16

Chronic Meds: 16

ACB Score: 2

SB Score: 3

Renal Function: UNKNOWN

LQTS Score: 0

Competitive Inhibition: 7

Total Risk Score: 21

IF ALL RECOMMENDATIONS ACCEPTED

14

14

1

2

UNKNOWN

0

3

12

Low Risk

High Risk

Prescriber Signature: _____

FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17